Abeona Therapeutics Reports $5.8M Revenue and $71.2M Net Income in 2025

Abeona Therapeutics Inc. reported significant financial developments in its recent 10-K filing, highlighting a pivotal year marked by the FDA's approval of its gene therapy product, ZEVASKYN®, for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). For the fiscal year ending December 31, 2025, the company generated total revenues of $5.8 million, a substantial increase from zero in the previous year, driven primarily by $2.4 million in product sales from ZEVASKYN® and $3.4 million in license and other revenues. The net income for the year was reported at $71.2 million, largely due to a $152.4 million gain from the sale of a priority review voucher, marking a significant turnaround from a net loss of $63.7 million in 2024.

The company’s operational expenses also saw notable changes, with total costs rising to $95.3 million from $64.2 million in the prior year. This increase was primarily attributed to a substantial rise in selling, general, and administrative expenses, which surged to $65 million, reflecting the costs associated with the commercialization of ZEVASKYN® and the expansion of the workforce. Research and development expenses decreased to $26.8 million from $34.4 million, as costs related to clinical trials transitioned into capitalized inventory following the product's approval.

Strategically, Abeona has focused on expanding its network of qualified treatment centers for ZEVASKYN®, with four centers activated as of March 2026. The company is also advancing its pipeline of AAV-based gene therapies targeting ophthalmic diseases, including ABO-503 for X-linked retinoschisis and ABO-504 for Stargardt disease. The company has engaged in collaborations with academic institutions and other organizations to enhance its research and development capabilities, which are critical for its long-term growth strategy.

Looking ahead, Abeona anticipates continued investment in the commercialization of ZEVASKYN® and the development of its pipeline products. The company has expressed confidence in its ability to navigate the complexities of the gene therapy market, although it acknowledges the inherent risks associated with regulatory approvals and market acceptance. The management's outlook emphasizes the importance of securing additional funding to support ongoing operations and development efforts, as the company continues to work towards achieving profitability in the coming years.